SANUWAVE offers two FDA-approved wound care products. Credit: VGstockstudio / Shutterstock.com.

Medical device company SANUWAVE Health has signed a definitive merger agreement with special purpose acquisition company SEP Acquisition (SEPA).

The proposed deal values the combined entity at an enterprise value of $127.5m.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The merged company is anticipated to run under the name SANUWAVE after the intended transaction is concluded.

SANUWAVE’s investors are expected to hold roughly 69.6% of the new company’s equity if the combined entity receives approximately $13m in gross proceeds upon completion.

SANUWAVE CEO Morgan Frank said: “SEPA is a strong, value-add partner and this transaction will allow SANUWAVE to simplify its capital structure and gain a listing on the Nasdaq Capital Market while funding the company for the exciting growth ahead.

“This is the next step in putting the company on sound footing that will allow us to focus on rapid, profitable growth and to garner an equity valuation commensurate with our performance.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

SANUWAVE offers two wound care products that are approved by the US Food and Drug Administration (FDA).

Its main product is the UltraMIST system, a low-frequency, non-contact ultrasound system that offers energy through a fluid mist.

This device has nationwide schedule 1 reimbursement from the Centers for Medicare & Medicaid Services, a part of the Department of Health and Human Services.

SEPA CEO Andrew White said: “We believe very strongly in this company and the UltraMIST product and look forward to being a part of SANUWAVE’s future success.”

Subject to the satisfaction of the agreed-upon closing conditions, the deal is anticipated to be completed in the fourth quarter (Q4) of this year.